Antoine Italiano

Featured in: Favicon

nature.com Favicon

jamanetwork.com Favicon

oxfordjournals.org Favicon

thelancet.com Favicon

healio.com Favicon

aacrjournals.org Favicon

ejcancer.com + 6 more

Articles

Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial - Nature Medicine

May 24, 2024 | nature.com | Jordi Rodon |Silvia Damian |Jesús García-Donas |Antoine Italiano |Iben Spanggaard |Tomoya Yokota | +1 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-02934-7, published online 6 May 2024In the version of the article initially published, patient numbers and ratios of the trial cohorts were missing from the abstract and have now been added in the HTML and PDF versions of the article.
Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial - Nature Medicine

May 6, 2024 | nature.com | Jordi Rodon |Silvia Damian |Jesús García-Donas |Antoine Italiano |Iben Spanggaard |Tomoya Yokota | +1 more

AbstractFibroblast growth factor receptor (FGFR) alterations drive oncogenesis in multiple tumor types. Here we studied pemigatinib, a selective, potent, oral FGFR1–FGFR3 inhibitor, in the phase 2 FIGHT-207 basket study of FGFR-altered advanced solid tumors. Primary end points were objective response rate (ORR) in cohorts A (fusions/rearrangements) and B (activating non-kinase domain mutations).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →